Summary of Study ST000433

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000335. The data can be accessed directly via it's Project DOI: 10.21228/M8HS40 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000433
Study TitlePlasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
Study Typetargeted sphingolipid and fatty acid analyses
Study SummaryWe identified four groups with available plasma 2 years before death: high (n = 12) and intermediate-likelihood DLB (n = 14) based on the third report of the DLB consortium; dementia with Alzheimer's pathology (AD; n = 18); and cognitively normal with normal aging pathology (n = 21). Lipids were measured using ESI/MS/MS.
Institute
Mayo Clinic
DepartmentDepartment of Neurology
LaboratoryMayo Clinic Metabolomics Resource Core
Last NameMielke
First NameMichelle
Address200 First Street SW, Rochester, MN 55905
EmailMielke.Michelle@mayo.edu
Phone507-293-1069
Submit Date2016-07-22
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2016-09-23
Release Version1
Michelle Mielke Michelle Mielke
https://dx.doi.org/10.21228/M8HS40
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000335
Project DOI:doi: 10.21228/M8HS40
Project Title:Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
Project Type:targeted sphingolipid and fatty acid analyses
Project Summary:The clinical and pathological phenotypes of Dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) often overlap. We examined whether plasma lipids differed among individuals with autopsy-confirmed Lewy Body pathology or AD pathology.
Institute:Mayo Clinic
Department:Department of Neurology
Laboratory:Mayo Metabolomics Core
Last Name:Mielke
First Name:Michelle
Address:200 First Street SW, Rochester, MN 55905
Email:Mielke.Michelle@mayo.edu
Phone:507-293-1069

Subject:

Subject ID:SU000454
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Group
SA021744sample57Alzheimer disease dementia
SA021745sample54Alzheimer disease dementia
SA021746sample58Alzheimer disease dementia
SA021747sample59Alzheimer disease dementia
SA021748sample56Alzheimer disease dementia
SA021749sample65Alzheimer disease dementia
SA021750sample52Alzheimer disease dementia
SA021751sample55Alzheimer disease dementia
SA021752sample60Alzheimer disease dementia
SA021753sample62Alzheimer disease dementia
SA021754sample69Alzheimer disease dementia
SA021755sample68Alzheimer disease dementia
SA021756sample67Alzheimer disease dementia
SA021757sample61Alzheimer disease dementia
SA021758sample64Alzheimer disease dementia
SA021759sample53Alzheimer disease dementia
SA021760sample63Alzheimer disease dementia
SA021761sample66Alzheimer disease dementia
SA021762sample1Cognitively normal
SA021763sample20Cognitively normal
SA021764sample7Cognitively normal
SA021765sample8Cognitively normal
SA021766sample9Cognitively normal
SA021767sample6Cognitively normal
SA021768sample5Cognitively normal
SA021769sample2Cognitively normal
SA021770sample3Cognitively normal
SA021771sample4Cognitively normal
SA021772sample10Cognitively normal
SA021773sample11Cognitively normal
SA021774sample17Cognitively normal
SA021775sample18Cognitively normal
SA021776sample19Cognitively normal
SA021777sample16Cognitively normal
SA021778sample15Cognitively normal
SA021779sample12Cognitively normal
SA021780sample13Cognitively normal
SA021781sample14Cognitively normal
SA021782sample21Cognitively normal
SA021783sample27Dementia with Lewy Bodies
SA021784sample25Dementia with Lewy Bodies
SA021785sample26Dementia with Lewy Bodies
SA021786sample24Dementia with Lewy Bodies
SA021787sample23Dementia with Lewy Bodies
SA021788sample22Dementia with Lewy Bodies
SA021789sample28Dementia with Lewy Bodies
SA021790sample29Dementia with Lewy Bodies
SA021791sample33Dementia with Lewy Bodies
SA021792sample32Dementia with Lewy Bodies
SA021793sample31Dementia with Lewy Bodies
SA021794sample30Dementia with Lewy Bodies
SA021795sample34Dementia with Lewy Bodies
SA021796sample35Mixed DLB and AD
SA021797sample40Mixed DLB and AD
SA021798sample41Mixed DLB and AD
SA021799sample42Mixed DLB and AD
SA021800sample39Mixed DLB and AD
SA021801sample38Mixed DLB and AD
SA021802sample36Mixed DLB and AD
SA021803sample37Mixed DLB and AD
SA021804sample43Mixed DLB and AD
SA021805sample44Mixed DLB and AD
SA021806sample49Mixed DLB and AD
SA021807sample50Mixed DLB and AD
SA021808sample48Mixed DLB and AD
SA021809sample47Mixed DLB and AD
SA021810sample45Mixed DLB and AD
SA021811sample46Mixed DLB and AD
SA021812sample51Mixed DLB and AD
Showing results 1 to 69 of 69

Collection:

Collection ID:CO000448
Collection Summary:All blood samples in the Mayo Clinic ADRC are collected from nonfasting participants in the sitting position in a clinical laboratory. Serum tubes (red-top) are drawn first, followed by EDTA plasma tubes. Blood is drawn from the median cubital vein with a 21 g needle and typically centrifuged at 2000 g for 10 minutes at 4°C. The serum and plasma are aliquoted into 0.5 mL and stored in a −80°C freezer until use. None of the aliquots were thawed before being pulled to measure the sphingolipids and fatty acids. We have previously shown that long-term storage, up to 38 years, in long-term −80°C freezers does not affect sphingolipid levels [26].
Sample Type:Blood

Treatment:

Treatment ID:TR000468
Treatment Summary:All individuals were enrolled in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and donated their brain to the Neuropathology Core. Eligibility criteria for the proposed study included an autopsy report and available blood at the last study visit before death. Standardized methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) [20], [21] and the Consortium to Establish a Registry for Alzheimer's Disease guidelines [22]. Braak neurofibrillary tangle (NFT) stage was determined based on the distribution of NFTs assessed with Bielschowsky silver stain [23]. A consensus clinical diagnosis was determined at each study visit by a panel of neurologists, neuropsychologists, and nurses who reviewed all patient information including neuropsychological results, activities of daily living, and the Clinical Dementia Rating scale. The diagnosis of dementia was based on DSM-III-R criteria [24]. We identified the following four groups: (1) Cognitively normal-normal pathology [CN, n = 21]. These individuals had no LBs, had low-likelihood AD according to the National Institute of Aging (NIA)-Reagan Criteria [25], and were cognitively normal as of their last study visit. (2) High-likelihood DLB [n = 13]. These individuals met criteria for high-likelihood DLB according to the CDLB, had Braak NFT stage ≤ IV, low to intermediate-likelihood AD, and a diagnosis of dementia as of the last study visit. Twelve patients had diffuse LB and one had transitional LB. (3) Intermediate-likelihood DLB (n = 17). These individuals had both DLB and AD pathologies. They had transitional (n = 14) or diffuse (n = 3) LBs, met criteria for intermediate-likelihood DLB according to the CDLB, had Braak NFT stage ≥ IV, intermediate to high-likelihood AD, and a diagnosis of dementia as of the last study visit. (4) Alzheimer's disease pathology (AD, n = 18). These individuals had high (n = 16) or intermediate (n = 2) likelihood AD according to NIA-Reagan criteria, had Braak NFT stage ≥ IV, no LBs, and had a diagnosis of probable AD dementia. Given our previous report that plasma ceramides increase with age and are higher in women [26], we frequency matched the four groups by sex and also by age.

Sample Preparation:

Sampleprep ID:SP000461
Sampleprep Summary:The lipids were extracted from 200 μL of plasma after the addition of internal standards.

Combined analysis:

Analysis ID AN000683
Analysis type MS
Chromatography type Reversed phase
Chromatography system Thermo TSQ Quantum Ultra
Column Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Thermo Quantum Ultra
Ion Mode POSITIVE
Units micromolar

Chromatography:

Chromatography ID:CH000495
Chromatography Summary:The targeted sphingolipid and fatty acid analyses were conducted by the Mayo Clinic Metabolomics Core. Electrospray ionization mass spectrometry was used to quantify plasma ceramides, sphinganine, sphingosine, sphingosine-1-phosphate (S1P), monohexosylceramides, and free fatty acids. The lipids were extracted from 200 μL of plasma after the addition of internal standards. The extracts were measured against a standard curve on the Thermo TSQ Quantum Ultra mass spectrometer (West Palm Beach, FL) coupled with a Waters Acquity UPLC system (Milford, MA) and quantified in μM units.
Instrument Name:Thermo TSQ Quantum Ultra
Column Name:Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS000609
Analysis ID:AN000683
Instrument Name:Thermo Quantum Ultra
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo